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Abstract 
In developing countries, infectious diseases are a major cause of mortality in children. Vaccines able to control diseases 
primarily affecting developing countries are often not available, due to the lack of commercial incentives to invest on 
their development. The Novartis Vaccines Institute for Global Health (NVGH) was created at the beginning of 2008 with 
the non for profit mission of developing effective and affordable vaccines for neglected infectious diseases of developing 
countries. NVGH is co-located with Novartis Vaccines in Siena, Italy and has access to all assets and know how used by 
Novartis for vaccine development. Therefore, one of NVGH’s major strengths is the ability to bring the industrial best 
practices, the technical know how and the physical resources needed for reliably developing new vaccines. NVGH’s 
current focus is on the development of new vaccines against diarrheal diseases which cause a high burden in developing 
countries. In particular NVGH is developing new vaccines against Salmonella (Typhoid Fever, Paratyphoid Fever and 
Non Typhoid Salmonella), Shigella and related diseases. As part of the international vaccine community, in addition to 
vaccine development, NVGH is very committed to capacity building and educational activities and organizes PhD 
programs, Masters and undergraduate programs. Among these programs, the post graduate Masters on Vaccinology and 
Pharmaceutical Clinical Development is primarily designed for medical doctors from developing countries. 
.
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1.  Introduction  
Morbidity and mortality caused by infectious diseases disproportionately affect the poorest populations of the world. As 
a matter of fact, 98.9 % of DALYS and 96.9 % of deaths due to infectious diseases occur in the middle and low income 
countries [1]. Not only infectious diseases are more likely to affect the poorer populations, but, due to a vicious circle 
caused by the huge toll extracted from the income of each family, they further increase the level of poverty of these 
populations [2].  
In addition, infectious diseases disproportionately affect the youngest populations and in fact 54% of DALYS and 43% 
of deaths from infectious disease are in < 5 year old children; this is 10.8 fold as many DALYs per 1000 population and 
16.4 fold as many deaths per 1000 population compared to > 5 year old subjects [1]. Interestingly, this excess of 
morbidity and mortality in poor and young populations is not seen with non infectious diseases [1]. 
* Corresponding author. E-mail address: audino.podda@novartis.com
A. Podda / Procedia in Vaccinology 2 (2010) 124–127 125
0
10.000.000
20.000.000
30.000.000
40.000.000
50.000.000
60.000.000
70.000.000
Tu
be
rc
ulo
sis
Ma
lar
ia
HIV
/AI
DS
ST
Ds
 
ex
clu
din
g H
IV
Dia
rrh
oe
al 
dis
ea
se
s
Lo
we
r r
es
pir
ato
ry 
inf
ec
tion
s
Up
pe
r r
es
pir
ato
ry 
inf
ec
tion
s
Ot
itis
 
m
ed
ia
Ch
ildh
oo
d-c
lus
ter
 
dis
ea
se
s
Me
as
les
Me
nin
git
is
He
pa
titis
 B
He
pa
titis
C
Tro
pic
al-
clu
ste
r d
ise
as
es
Le
pro
sy
De
ng
ue
Ja
pa
ne
se
 
en
ce
ph
alit
is
Tra
cho
m
a
Int
es
tin
al 
ne
m
ato
de
 
inf
ec
tio
ns
Ot
he
r in
fec
tiou
s d
ise
as
es
D
A
L
Y
s
Figure 1. Infectious diseases causing the greatest burden in < 5 year old children. Global DALYs
Therefore, infectious diseases are a major cause of mortality in children of developing countries and, as shown in Figure
1, the greatest burden is caused by respiratory and diarrheal diseases. Although some of these diseases are vaccine 
preventable, for many of them effective vaccines are not available due to the lack of commercial incentives to stimulate 
sufficient investment for development of new vaccines against those diseases which primarily affect developing 
countries. 
2. The Novartis Vaccines Institute for Global Health
As part of Novartis’s corporate citizenship commitment, several programs for improving global access to medicines have 
been funded. Among them, some programs are specifically aimed to make available drugs for the treatment of deadly 
infectious diseases such as malaria, leprosy and tuberculosis or to discover new drugs for tropical diseases at the Novartis 
Institute for Tropical Diseases (NITD) in Singapore.  
The Novartis Vaccines Institute for Global Health (NVGH), inaugurated at the beginning of 2008, is aimed to develop 
effective and affordable vaccines for neglected diseases of developing countries with the objective to improve global 
health. 
NVGH is a separate organization with its own in house capacity for vaccine discovery, process development, pilot scale 
production and clinical development. However, being co-located in the same campus of Novartis Vaccines & 
Diagnostics in Siena, Italy, is the only institute in the world dedicated to development of vaccines for neglected diseases 
with a direct access to facilities, know-how and technologies of a major vaccine manufacturer. 
NVGH works with research institutions, clinical organizations in developing countries, local manufacturers of 
developing countries and national and international health organizations to develop vaccines for diseases that are not 
associated to sufficient commercial incentives to stimulate adequate investments ensure rapid vaccine development. 
Starting from a laboratory concept, NVGH will undertake the technical development and the clinical testing program to 
fully characterize the clinical profile of the candidate vaccine in the developing countries where the disease is endemic 
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and will be ultimately used in order to subsequently work together with partner manufacturers for large scale production.  
With the support of external funding partners, NVGH aims to reduce the development risk and the cost of new vaccines 
and to make them more affordable for impoverished communities.  
3.  Vaccine development programs  
NVGH does not perform the basic research to identify vaccine targets, but rather build on novel ideas coming from the 
scientific community on which NVGH industrial know-how for vaccine development can be applied. The criteria 
adopted for the selection of new projects include the likelihood of the candidate new vaccine to: i) generate protective 
immunity, ii) be produced at manufacturing scale and iii) have enough priority in developing countries to guarantee 
uptake.
With respect to last point, priority in developing countries, another important element of consideration for NVGH is to 
focus on those high priority diseases which are most neglected (i.e., diseases with a high ‘burden of disease/R&D 
funding availability’ ratio). As can be seen in Figure 1, two types of diseases, pneumonia and diarrhea, cause over 50% 
of the DALYS in < 5 year old children and diarrhea alone kills more children than HIV, Tuberculosis and Malaria 
combined. By contrast, compared to HIV, Tuberculosis and Malaria, diarrheal diseases are much more neglected from an 
R&D funding perspective [2]. For this reason, NVGH decided to have its initial projects in the area of diarrheal and 
enteric diseases. These diseases are globally responsible for over four and a half billion cases of diarrhea every year and 
have a particularly high burden in developing countries. Current NVGH projects are aimed to develop new vaccines 
against Salmonella and Shigella related diseases, with a plan to expand to new targets in the near future. 
Salmonella vaccine projects. Currently available typhoid vaccines do not work for children under the age of two and do 
not protect against paratyphoid fever.  This is an important limitation as in endemic countries a significant number of 
cases occur in young children and the incidence of S. paratyphi A is significantly increasing. In order to meet this unmet 
need, NVGH is developing both a monovalent S. typhi conjugate vaccine (which is now ready to start clinical 
development) and a bivalent conjugate vaccine which also includes the S. paratyphi A component. These vaccines, when 
available, will be administered to infants and will allow incorporation in the infant EPI immunization schedule and 
consequently a high vaccine coverage which is difficult to achieve with current vaccines. In addition to the vaccines 
against enteric fever, NVGH, using the same conjugation technology, is also developing a vaccine against non-typhoidal 
Salmonella (NTS). NTS is an important cause of invasive disease, particularly in sub Saharan Africa, where Salmonella 
typhimurium and Salmonella enteritidis are among the most common causes of bacteraemia and sepsis in young 
children. 
Shigella vaccine project. According to the World Health Organization, shigellosis is responsible annually for 
approximately 165 million cases of severe disease world wide and more than 1 million deaths. Most of these cases occur 
in developing countries in children under the age of five. No vaccine is currently available and the prevalence of 
antibiotic resistance in Shigella isolates is increasing. NVGH aims to develop a low-cost, protein-based vaccine that is 
broadly protective against most or ideally all of the different Shigella serotypes.
4.  Training and capacity building activities 
As a member of the international vaccine community, NVGH is highly committed to offer training opportunities on all 
aspects of vaccine development including basic research, translational research, technical development, clinical and 
regulatory development and public health. Among courses available are: i) laboratory based Master Degree in Science 
for MSc students aimed to conduct research on the development of novel vaccines against Salmonella and Shigella; ii) 
PhD programs for students who, following admission to a PhD program by several Italian Universities, can choose a 
NVGH fellowship to carry out scientific research in the field of vaccine development; iii) Post doctoral programs like the 
Masters in Vaccinology and Pharmaceutical Clinical Development which is aimed to prepare post graduate medical 
students for a career in academia, public health or in vaccine clinical development and is preferentially designed for 
medical doctors from developing countries. 
More specifically, the Masters in Vaccinology is a two-year program jointly organized by the University of Siena, 
Medical School and Novartis and is fully sponsored by Novartis. The students are provided with training on all aspects of 
developing vaccines, including immunology, infectious diseases, clinical research methodology, epidemiology, 
biostatistics, clinical data management, regulatory and manufacturing aspects. The first year is dedicated to classroom 
sessions with academicians,  scientists and researchers with years of experience in clinical infectious diseases, basic 
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research and clinical research & development of new vaccines while the second year is a ‘full immersion’ in real life 
clinical and regulatory activities within the company clinical development teams to which the students will be assigned. 
Aiming to perform most of its clinical trials in developing countries, NVGH is aware of the several challenges that will 
have to be faced including, among others, the need to: i) achieve results that are scientifically sound and qualitatively 
credible from a regulatory perspective; ii) adopt the highest ethical standards and iii) feeling the responsibility towards 
education and progression in medical science in developing world (capacity building). With respect to capacity building 
activities, not only NVGH is committed to the training and educational in house programs outlined above, but also to be 
financially accountable for local training, refurbishment of facilities and laboratory technological advancement for a 
sustainable development of clinical sites in developing countries. 
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